Autolus Therapeutics

AUTL

Market cap $370M

LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company's Board of Directors.

The U.K.'s National Institute for Health and Care Excellence (NICE) published on Tuesday draft guidance recommending Autolus Therapeutics plc's (NASDAQ: AUTL) Aucatzyl (obecabtagene autoleucel, or obe-cel) for use in the National Health Service (NHS) for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for Health and Care Excellence (NICE) has published draft guidance1 recommending AUCATZYL® (obecabtagene autoleucel, or “obe-cel”)2 for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). AUCATZYL will be available through routine commissioning by the NHS.

Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London.

Autolus Therapeutics plc ( AUTL ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Amanda Cray Christian Itin - CEO & Director Robert Dolski - Senior VP, CFO & Principal Accounting Officer Conference Call Participants Asthika Goonewardene - Truist Securities, Inc., Research Division Gil Blum - Needham & Company, LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Yuxi Dong - Jefferies LLC, Research Division Madeleine Stone - William Blair & Company L.L.C., Research Division Shyam Kotadia - Goldman Sachs Group, Inc., Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Good day.

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation to support market growth and expansion continues; data in severe refractory systemic lupus erythematosus (srSLE) show no ICANS or high-grade CRS, demonstrate achievement of definition of remission in SLE (DORIS) in 83% (n=5/6) of patients and complete renal response (CRR) in 50% (n=3/6) of patients Leadership team bolstered to support next phase of growth and optimization of business operations Conference call to be held today at 8:30 am EST / 1:30 pm GMT; conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the third quarter ended September 30, 2025.

Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of five abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2025, in Orlando, Florida.

LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its third quarter 2025 financial results and operational highlights before open of U.S. markets on Wednesday, November 12, 2025.